慢性心力衰竭患者血清miR-224-5p和miR-106a-5p水平及其与短期预后的关系

    Levels of serum miR-224-5p and miR-106a-5p and their relationship with short-term prognosis in patients with chronic heart failure

    • 摘要:
      目的 探究慢性心力衰竭(chronic heart failure,CHF)患者血清miR-224-5p和miR-106a-5p水平及其与短期预后的关系。
      方法 选取2020年1月~2023年12月于本院进行治疗的CHF患者173例作为研究组,根据预后情况分为预后良好组(98例)和预后不良组(75例),选择同期健康体检人员89例作为对照组。使用qRT-PCR法对血清miR-224-5p和miR-106a-5p水平进行检测并进行比较,使用Pearson相关性分析血清miR-224-5p和miR-106a-5p水平之间以及与心功能指标的相关性,使用Logistic回归分析CHF患者预后不良的影响因素,使用ROC分析血清N末端B型利钠肽原(N-terminal B-type natriuretic peptide precursor,NT-proBNP)、miR-224-5p和miR-106a-5p水平对CHF患者预后不良的诊断价值。
      结果 与对照组相比,研究组的血清miR-224-5p水平明显升高,血清miR-106a-5p水平明显降低(均P<0.01)。预后良好组的心输出量(cardiac output,CO)、左心室射血分数(left ventricular ejection fraction,LVEF)和miR-106a-5p明显高于预后不良组,左心室舒张末期内径(left ventricular end diastolic diameter,LVEDD)、左心房内径(left atrial diameter,LAD)、左心室后壁厚度(left ventricular posterior wall thickness,LVPW)、左心室质量指数(left ventricular mass index,LVMI)、NT-proBNP和miR-224-5p明显低于预后不良组(均P<0.01);预后不良组血清miR-224-5p与miR-106a-5p水平、CO和LVEF呈负相关,与LVEDD、LAD、LVPW、LVMI和NT-proBNP呈正相关,miR-106a-5p水平与CO和LVEF呈正相关,与LVEDD、LAD、LVPW、LVMI和NT-proBNP呈负相关(均P<0.01);Logistic分析表明,CO(P<0.05)、LVEF(P<0.05)和miR-106a-5p(P<0.01)是CHF患者预后不良的保护因素,LVEDD、LAD、LVPW、LVMI、NT-proBNP和miR-224-5p是CHF患者预后不良的危险因素(均P<0.05)。ROC分析显示,血清NT-proBNP、miR-224-5p和miR-106a-5p水平诊断CHF患者预后不良的AUC为0.859、0.854和0.869,三者联合诊断的AUC为0.938,明显高于三者单独诊断(均P<0.05)。
      结论 CHF患者血清miR-224-5p水平明显上调,miR-106a-5p水平明显下调,均与心功能指标密切相关,且联合NT-proBNP对CHF患者预后不良具有良好的诊断价值。

       

      Abstract:
      AIM To investigate the levels of serum miR-224-5p and miR-106a-5p in patients with chronic heart failure (CHF) and their relationship with short-term prognosis.
      METHODS One hundred and seventy-three CHF patients who received treatment in our hospital from January 2020 to December 2023 were included in the study. They were divided into good prognosis group (98 cases) and poor prognosis group (75 cases) based on their prognosis. Eighty-nine healthy individuals who underwent physical examinations served as the control group. QRT-PCR method was used to measure and compare the levels of serum miR-224-5p and miR-106a-5p and Pearson correlation was used to analyze the correlation between serum miR-224-5p and miR-106a-5p levels and their correlation with cardiac function indicators. Logistic regression was applied to analyze the influencing factors of poor prognosis in CHF patients and ROC was applied to analyze the diagnostic value of serum NT-proBNP, miR-224-5p and miR-106a-5p levels for poor prognosis in CHF patients.
      RESULTS Compared with the control group, the serum miR-224-5p level in the study group was significantly increased, while the serum miR-106a-5p level was significantly decreased (both P<0.01).The cardiac output (CO), left ventricular ejection fraction (LVEF), and miR-106a-5p of the good prognosis group were significantly higher than those of the poor prognosis group. The left ventricular end diastolic diameter (LVEDD), left atrial diameter (LAD), left ventricular posterior wall thickness (LVPW), left ventricular mass index (LVMI), NT proBNP, and miR-224-5p were significantly lower than those of the poor prognosis group (all P<0.01); The serum miR-224-5p levels in the poor prognosis group were negatively correlated with miR-106a-5p levels, CO, and LVEF, and positively correlated with LVEDD, LAD, LVPW, LVMI, and NT proBNP. miR-106a-5p levels were positively correlated with CO and LVEF, and negatively correlated with LVEDD, LAD, LVPW, LVMI, and NT proBNP (all P<0.01); Logistic analysis showed that CO (P<0.05), LVEF (P<0.05), and miR-106a-5p (P<0.01) were protective factors for poor prognosis in CHF patients, while LVEDD, LAD, LVPW, LVMI, NT proBNP, and miR-224-5p were risk factors for poor prognosis in CHF patients (all P<0.05). ROC analysis showed that the AUC values of serum NT proBNP, miR-224-5p, and miR-106a-5p levels for diagnosing poor prognosis in CHF patients were 0.859, 0.854, and 0.869, respectively. The AUC value for the combined diagnosis of the three was 0.938, which was significantly higher than that for the individual diagnosis of the three (all P<0.05).
      CONCLUSION The serum miR-224-5p level is prominently up-regulated and miR-106a-5p level is prominently down-regulated in CHF patients, both are closely related to cardiac function indicators. Their combination with NT-proBNP has good diagnostic value for poor prognosis in CHF patients.

       

    /

    返回文章
    返回